Helical, a London-based startup, has successfully secured $10 million in seed funding to enhance the application of bio foundation models in pharmaceutical research.
The funding round, led by redalpine and supported by notable angel investors including Aidan Gomez and Clément Delangue, aims to expand Helical's collaborations with major pharmaceutical companies. The startup is already working with several top-20 global pharma firms, including a public partnership with Pfizer focused on predictive biomarkers and collaborations with Tanabe Pharma America for neurodegenerative disease research.
Founded by three childhood friends from Luxembourg, Helical addresses a critical gap in the integration of AI models with practical applications in drug discovery. The founders bring diverse expertise, from technology development at Amazon to data science at IBM and cardiology research. Their platform features a Virtual Lab for biologists and a Model Factory for data scientists, designed to streamline workflows and enhance reproducibility in research.
Helical’s innovative approach aims to significantly reduce drug discovery timelines, leveraging the potential of bio foundation models trained on extensive biological datasets. With global pharma R&D expenditures exceeding $300 billion annually, the startup's solutions could prove pivotal in overcoming the inefficiencies that plague traditional research methodologies.